Skip to main content
. Author manuscript; available in PMC: 2009 Sep 9.
Published in final edited form as: Cancer Cell. 2008 Sep 9;14(3):263–273. doi: 10.1016/j.ccr.2008.08.001

Figure 2. Evaluation of CEPs in mice treated with either paclitaxel or gemcitabine in combination with DC101.

Figure 2

(A) 8–10 week old non-tumor bearing C57Bl/6 mice (n=4 mice/group) were treated with 50mg/kg paclitaxel (PTX), or 500mg/kg gemcitabine (GEM). Blood was drawn from the retro-orbital sinus at time points indicated in the figure, and processed for the evaluation of viable CEPs using flow cytometry. (B) In a separate experiment, mice were treated with paclitaxel (PTX) or gemcitabine (GEM) as described in (A), with or without DC101 given 24 hours prior to chemotherapy treatment. Blood was drawn via retro-orbital sinus and processed for the evaluation of viable CEPs using flow cytometry. *, 0.05>p>0.01; **, p<0.01.